Enstilar Foam Supply Resumed

Following the temporary disruption in June, supply has now recommenced.

We have recently received an update from LEO Pharma, the manufacturers of Enstilar® (calcipotriol/betamethasone dipropionate) cutaneous foam 60g, to confirm that supply of the treatment has now recommenced following temporary disruption during June, caused by an unforeseen technical issue in the manufacturing process.

Fluctuations in supply are expected to continue whilst stock flow normalises, but the manufacturer will continue working to restore full supply as soon as possible. 

LEO Pharma advises any patients affected by ongoing fluctuations in product supply to return to their Healthcare Professional to discuss their personal needs, preferences and options in partnership with them.

Once again, there are no safety or quality issues with current stock; available stock can be dispensed and used.

You can find more information about currently unavailable treatments here.